Novo Nordisk's Pipeline Showdown: Can CagriSema and Zenagamtide Reverse the Stock's Slide?

Novo Nordisk unveils CagriSema Phase 3 data at ADA after stock drop; oral Wegovy pill shows strong early prescriptions, but valuation and pricing pressures persist.

A beleaguered stock, a packed clinical calendar, and a commercial bright spot in pill form — Novo Nordisk enters the first week of June with more than just abstracts to present at the American Diabetes Association’s 86th Scientific Sessions in New Orleans. For investors who have watched the Danish drugmaker shed 36% of its value over the past twelve months, the data due from Friday onward will either validate the long-term growth thesis or deepen the doubt.

The ADA conference, running from June 5 to 8, will see Novo Nordisk unveil 40 abstracts. The headline acts are the Phase 3 data from the REIMAGINE 1–3 studies for CagriSema — a weekly injectable combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, targeting type 2 diabetes, obesity, and weight management. Alongside it, Phase 2 results for Zenagamtide, another weekly dual-mechanism candidate, will also be presented. The company has scheduled a dedicated R&D investor webcast on Sunday, June 7, from 4:30 to 6:00 p.m. CDT to contextualise the findings.

These readouts come at a time when the broader market for weight-loss drugs has shifted. Pure demand stories are no longer enough. European healthcare stocks have fallen 5% so far this year, with Novo Nordisk down 14% and Eli Lilly off 1.5%, according to Cinco Días. Pricing pressure and intensifying competition are squeezing margins. Novo’s first-quarter results laid the tension bare: reported revenue climbed 32% at constant currencies, but that included a one-time benefit from the US 340B drug pricing programme. Excluding that effect, adjusted revenue actually contracted 4%. Higher volumes failed to fully offset lower prices, though adjusted obesity sales still managed a 22% increase.

Against that backdrop, the commercial performance of the oral Wegovy pill offers a rare positive. In its first week on the US market, the tablet generated roughly 18,410 prescriptions, dwarfing the 3,707 that Eli Lilly’s oral competitor Foundayo managed in its own launch window. Crucially, about 80% of Wegovy pill users were new to GLP-1 therapy, suggesting the oral formulation is expanding the patient pool rather than cannibalising existing injections. Regulatory momentum is also building: on May 22, the European Medicines Agency’s CHMP recommended approval for both Wegovy HD — the higher 7.2 mg dose — and the Wegovy pill.

Yet the stock has been unable to shake off the weight of the past year. At the end of last week, Novo Nordisk shares closed at €39.05, virtually flat on the day. The price stands 44% below its 52-week high of €70.13, though it has regained the 50-day moving average near €35. It still trades under the 200-day line at €42, and the relative strength index of 48 points to a neutral stance. A decisive break above the €39.50 resistance level — tested multiple times in recent days — would be a bullish signal. On a valuation basis, the trailing price-to-earnings multiple of 10.69 sits below the company’s own five-year median, reflecting the market’s scepticism.

The week ahead carries macro distractions as well. Eurostat will publish eurozone inflation data on June 2, and the US jobs report lands on June 5, coinciding with the first day of the ADA sessions. Moves in bond yields could colour sentiment across the entire healthcare sector. Novo Nordisk’s own guidance for 2026, raised in May, points to adjusted revenue and profit growth of between minus 4% and minus 12% at constant currencies, excluding the 340B effect — a forecast that leaves little room for disappointment on the clinical front.

With the FDA decision on CagriSema for weight management expected in the second half of the year and a Phase 3 trial for a high-dose version still to begin, the data from New Orleans will set the tone for the months ahead. The market will be watching not just the numbers, but whether Novo Nordisk can convince investors that its next-generation pipeline can withstand the pricing erosion and competitive onslaught that have already taken a heavy toll.